New GSK Chief Will Be "Most Powerful" UK Female CEO
Emma Walmsley will succeed Andrew Witty next year and become the seventh female chief executive in the FTSE 100.
GSK today announced that Emma Walmsley, currently Chief Executive Officer of GSK’s Consumer Healthcare division, has been appointed GSK CEO Designate and will succeed Andrew Witty when he retires on March 31, 2017. Walmlsey will join the GSK Board of Directors from January 1, 2017. She has been a member of GSK’s Corporate Executive Team since 2011, joining the company in 2010 from L’Oreal where she held a variety of marketing and general management roles in the UK, Europe and USA. From 2007 she was based in Shanghai as General Manager, Consumer Products for L’Oreal China. The appointment sees Walmsley, 47, become the seventh female chief executive in the FTSE 100, The Telegraph reported, and makes her "arguably the most powerful female boss in the index".
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
